Anti-Müllerian hormone: a new marker for ovarian function

Visser, Jenny A.; Jong, Frank H. de; Laven, Joop S.E.; Themmen, Axel P. N.

doi:10.1530/rep.1.00529

Cited by 721 publications

(512 citation statements)

References 59 publications

(32 reference statements)

Supporting

Mentioning

467

Contrasting

Unclassified

Order By: Relevance

“…Thus, AMH seems to downregulate two important steps of follicular development: follicle recruitment and cyclic selection for dominance [9,10]. Mouse studies have shown that AMH serum levels reflect the size of the primordial follicle pool and its reduction with aging [13,27]. In addition, human studies have shown that AMH directly correlates with the number of antral follicles assessed by ultrasound [5] and FSH, inhibin-B and estradiol [11].…”

Section: Introductionmentioning

confidence: 99%

Serum markers of ovarian reserve and ovarian histology in adult mice treated with cyclophosphamide in pre-pubertal age

Detti

Uhlmann

Lu³

et al. 2013

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose AMH is used to quantify the extent of follicular pool in postpubertal women, but its value after chemotherapy is unclear. We tested AMH as a marker of follicular reserve in adult mice treated with cyclophosphamide (CTX) in prepubertal age. Methods Mice received placebo or CTX at age 18 days. AMH and FSH were assessed on day 43, 56, and 95 of life. Ovaries were fixed in formalin, embedded in paraffin, and stained with H&E and TUNEL. Follicular apoptosis was graded. Results All mice exposed to CTX had a decreased number of follicles/mm 2 and significantly decreased AMH, but only 48 % of pubertal and 81 % of adult mice had increased FSH. Over time, there was an increase in FSH (p <0.05), but not a concurrent decrease in AMH, while in controls, FSH remained stable and AMH decreased. There was no correlation between histological and serological markers.Conclusions CTX administration to pre-pubertal mice caused various degrees of residual function, which were reflected by FSH, but not by AMH or by the number of ovarian follicles. AMH served as a marker of quantitative, and FSH of qualitative, residual ovarian function.

show abstract

Section: Introductionmentioning

confidence: 99%

Serum markers of ovarian reserve and ovarian histology in adult mice treated with cyclophosphamide in pre-pubertal age

Detti

Uhlmann

Lu³

et al. 2013

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…To determine ovarian reserve, anti-Mü llerian hormone (AMH) was identified as a reliable serum marker (10). It is produced by the granulosa cells of small growing follicles, reflects the size of the primordial follicle pool in the ovaries, and is an indicator of a woman's reproductive capacity (11). It is stable during and between menstrual cycles, in contrast to FSH (12,13,14), and is considered to be a valued marker for ovarian reserve, as it corresponds well with antral follicle count (AFC), which reflects reproductive status (10).…”

Section: Introductionmentioning

confidence: 99%

Decreased ovarian function is associated with obesity in very long-term female survivors of childhood cancer

Dorp

Blijdorp

Laven³

et al. 2013

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Obesity and gonadal dysfunction are known major side effects of treatment in adult childhood cancer survivors (CCS). In the general population, obesity has a negative influence on female fertility. We aimed to evaluate whether obesity and serum insulin are associated with decreased ovarian reserve markers in CCS. Design: Retrospective single-center cohort study. Methods: Data of 191 female survivors of childhood cancer were analyzed. Median follow-up time was 18.8 (2.3-48.8) years. Outcome measures were serum anti-Mü llerian hormone (AMH) and total follicle count (FC). Potential risk factors were: BMI; body composition measures, determined by dualenergy X-ray absorptiometry (total fat percentage, lean body mass, and visceral fat percentage); and fasting insulin. Results: Lower serum AMH was found in obese subjects (b (%) K49, PZ0.007) and in subjects with fasting insulin in the highest tertile (b (%) K43, PZ0.039). Total fat percentage tends to be associated with serum AMH (b (%) K2.1, PZ0.06). Survivors in the highest tertile of insulin had significantly lower FC than survivors in the lowest tertile (b K6.3, PZ0.013). BMI and other measures of body composition were not associated with FC. Correlation between serum AMH and antral follicle count (AFC) was rZ0.32 (PZ0.08). Conclusions: Obesity and insulin resistance are associated with gonadal damage, as reflected by decreased AMH and reduced FC in adult survivors of childhood cancer. In contrast to its highly predictive value for AFC in the healthy female population, serum AMH does not seem to correlate as well with AFC in CCS.European Journal of Endocrinology 168 905-912

show abstract

“…AMH appears to be the ideal marker for ovarian function and ovarian reserve reflecting the decline of reproductive age, as its levels are strongly correlated with the number of antral follicles detected by ultrasound [15] and are indicative of the size of the primordial follicle pool [16]. Concerning the field of reproductive medicine, extremely interesting new data on the possible clinical application of AMH measurement in the prediction of quantitative and qualitative ovarian response in ART have been published in the last few years, since AMH exhibits a relatively stable expression throughout the menstrual cycle [17].…”

mentioning

confidence: 99%

Single nucleotide polymorphisms in the Anti-Müllerian hormone (AMH Ile49Ser) and Anti-Müllerian hormone type II receptor (AMHRII −482 A>G) as genetic markers in assisted reproduction technology

Karagiorga

Partsinevelos

Mavrogianni

et al. 2014

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose The aim of the study was to evaluate whether the presence Antimullerian hormone (AMH) and Antimullerian hormone type II receptor (AMHRII) single nucleotide polymorphisms (SNPs) Ile 49 Ser and -482A>G respectively are related to the assisted reproduction outcome. Methods A prospective cross-sectional observational study was conducted in order to assess the distribution of AMH and AMHRII SNPs in two cohorts, one of healthy women (N=100) and the control group and the IVF/ICSI group (N=151) consisted of women undergoing IVF/ICSI treatment for infertility. Furthermore, a prospective longitudinal observational study was performed on the latter group to assess possible associations of these SNPs with patients' characteristics and controlled ovarian stimulation (COS) and pregnancy outcome. Results Among non-carriers of the AMH (Ile 49 Ser) polymorphism, basal FSH levels were lower in those with more than two of previous IVF attempts and fertilization rate was statistically higher in those with peak serum E2 levels below 1500 pg/ml, whereas among non-carriers of the AMHRII (−482 A>G) polymorphism, number of follicles was higher in those with more than two previous IVF attempts and total dose of gonadotropins was lower in those with peak serum E2 levels above 1500 pg/ml. Conclusions There was evidence that in specific subgroups of women undergoing IVF/ICSI, AMH and AMHRII SNPs may be related to patients' characteristics and controlled ovarian stimulation and pregnancy outcome and thus may provide a means for the prediction of ovarian response in specific subgroups of women entering an IVF/ICSI program.

show abstract

Anti-Müllerian hormone: a new marker for ovarian function

Cited by 721 publications

References 59 publications

Serum markers of ovarian reserve and ovarian histology in adult mice treated with cyclophosphamide in pre-pubertal age

Serum markers of ovarian reserve and ovarian histology in adult mice treated with cyclophosphamide in pre-pubertal age

Decreased ovarian function is associated with obesity in very long-term female survivors of childhood cancer

Single nucleotide polymorphisms in the Anti-Müllerian hormone (AMH Ile49Ser) and Anti-Müllerian hormone type II receptor (AMHRII −482 A>G) as genetic markers in assisted reproduction technology

Contact Info

Product

Resources

About